Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Rui Bi Da (rezivertinib)
i
Other names:
BPI-7711, BPI 7711, BPI-7711 capsule
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
Beta Pharma, CSPC Pharma
Drug class:
EGFR antagonist
Related drugs:
‹
CKD-702 (6)
SCT200 (4)
CPGJ-602 (3)
MCLA-158 (2)
cetuximab biosimilar (CDP-1) (0)
BTG-002814 (0)
KL 140 (cetuximab biosimilar) (0)
CKD-702 (6)
SCT200 (4)
CPGJ-602 (3)
MCLA-158 (2)
cetuximab biosimilar (CDP-1) (0)
BTG-002814 (0)
KL 140 (cetuximab biosimilar) (0)
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
EGFR T790M
Non Small Cell Lung Cancer
EGFR T790M
Non Small Cell Lung Cancer
rezivertinib
Sensitive: C3 – Early Trials
rezivertinib
Sensitive
:
C3
rezivertinib
Sensitive: C3 – Early Trials
rezivertinib
Sensitive
:
C3
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
rezivertinib
Sensitive: C3 – Early Trials
rezivertinib
Sensitive
:
C3
rezivertinib
Sensitive: C3 – Early Trials
rezivertinib
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.